Market Overview

Sanofi Regeneron Report Phase 3 ODYSSEY MONO trial with Alirocumab Met Primary Efficacy Endpoint

Related SNY
Sanofi Pasteur Announces FDA Approval of Fluzone® Intradermal Quadrivalent (Influenza Vaccine) for Adults
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO
Allergan Reportedly Seeks Alternate Suitor (Fox Business)

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.  The mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15.6%, p<0.0001).  In the trial, which employed a dose increase (up-titration) for patients who did not achieve an LDL-C level of 70 milligrams/deciliter (mg/dL), the majority of patients remained on the initial low dose of alirocumab of 75 milligrams (mg).

"We are excited with the findings from the first Phase 3 trial with alirocumab.  While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies, these monotherapy results are encouraging," said Jay Edelberg M.D., Ph.D., Head of the PCSK9 Development and Launch Unit, Sanofi Group.  "As in this trial, several of our Phase 3 studies will utilize an up-titration approach, the aim of which

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters